Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies (SIGA) maintains this dedicated news hub for stakeholders tracking developments in biodefense therapeutics and public health preparedness. Access verified updates about the company's oral antiviral TPOXX, government contracts, and international health security initiatives.
This resource consolidates official announcements including regulatory milestones, strategic partnerships, and financial performance reports. Investors and public health professionals will find timely information on:
• TPOXX approvals and distribution updates
• Government procurement contracts
• Clinical research developments
• Financial disclosures and earnings
• Global health collaboration announcements
All content is sourced directly from company filings and press releases to ensure accuracy. Bookmark this page for efficient tracking of SIGA's progress in developing countermeasures against orthopoxviruses and other high-consequence pathogens.
SIGA Technologies, Inc. (SIGA) announced a conference call scheduled for May 4, 2023, at 4:30 P.M. ET to provide a business update. The call will feature CEO Dr. Phil Gomez, Chief Scientific Officer Dr. Dennis Hruby, and CFO Daniel Luckshire. Interested participants can access the call via phone or a live webcast on SIGA's website. The company focuses on health security and its lead product, TPOXX®, is an antiviral drug for smallpox, recently approved in various formulations by the FDA and EMA. Notably, SIGA has contracts with the Biomedical Advanced Research and Development Authority (BARDA) for procurement and development linked to TPOXX®. The press release also includes forward-looking statements regarding contract risks and market conditions.
SIGA Technologies reported approximately $111 million in revenue for 2022, marking a decrease from $133.7 million in 2021. The company achieved $71 million in international product sales, a notable increase from $13 million in 2021. The introduction of IV TPOXX and oral TPOXX to the U.S. Government and Department of Defense contributed to this growth. SIGA generated a pre-tax operating income of approximately $43 million. Despite challenges posed by the pandemic, the company maintained its liquidity, although supply chain disruptions remain a risk. A conference call for further updates is scheduled for later today.
FAQ
What is the current stock price of Siga Technologie (SIGA)?
What is the market cap of Siga Technologie (SIGA)?
